{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-268041","form_type":"8-K","ticker":"CGEM","cik":"0001789972","company_name":"Cullinan Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.472649+00:00","generated_at":"2026-05-16T23:54:41.263792+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cullinan Q3 net loss $50.6M; focuses on T cell engagers; cash runway into 2029","bullets":["Net loss $50.6M vs $40.6M YoY; R&D expense $42.0M, G&A $13.6M.","Cash & investments $475.5M at Sept 30, 2025; runway expected into 2029.","CLN-049 showed ~30% CRc in R/R AML; oral presentation at ASH 2025.","CLN-978 initial SLE & RA safety/B-cell data expected H1 2026.","Discontinued CLN-619 and CLN-617; partner Taiho plans NDA for zipalertinib by year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-268041","json":"https://secwatch.observer/filing/0001193125-25-268041.json","markdown":"https://secwatch.observer/filing/0001193125-25-268041.md","text":"https://secwatch.observer/filing/0001193125-25-268041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/0001193125-25-268041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789972/000119312525268041/cgem-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:54:41.263792+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}